Stockscreener 앱 받기
0.3002
0.81%
-0.0038
전일 마감가:
$0.304
열려 있는:
$0.3065
하루 거래량:
189.57K
Relative Volume:
0.65
시가총액:
$23.91M
수익:
$1.22M
순이익/손실:
$-14.15M
주가수익비율:
-1.1546
EPS:
-0.26
순현금흐름:
$-6.55M
1주 성능:
+3.63%
1개월 성능:
+7.89%
6개월 성능:
-17.88%
1년 성능:
-42.01%
1일 변동 폭
$0.3001
$0.314
1주일 범위
$0.29
$0.314
52주 변동 폭
$0.2525
$0.62
IGC Pharma Inc Stock (IGC) Company Profile
명칭
IGC Pharma Inc
전화
301-983-0998
주소
4336 Montgomery Avenue, Bethesda, MD
IGC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.3001 | 23.91M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.77 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.83 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
539.64 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
265.93 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.90 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
IGC Pharma Inc 주식(IGC)의 최신 뉴스
IGCPharma (IGC) Confirms Genetic Safety of Alzheimer's Drug Ingr - GuruFocus
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC - GuruFocus
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting - ACCESS Newswire
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
Is IGC Pharma Inc (IGC) a good investment opportunity? - uspostnews.com
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - ACCESS Newswire
IGC Pharma Welcomes Strategic Investment from Advisors - PharmiWeb.com
IGC Pharma (IGC) Secures $475K Investment to Advance Alzheimer's Trial | IGC Stock News - GuruFocus
IGC Pharma Welcomes Strategic Investment from Advisors | IGC Sto - GuruFocus
IGC Pharma Welcomes Strategic Investment From Advisors - Barchart.com
IGC Pharma Welcomes Strategic Investment from Advisors | IGC Stock News - GuruFocus
The 7 Best Stocks Under 50 Cents To Buy For May 2025! - The Stock Dork
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporti - GuruFocus
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs | IGC Stock News - GuruFocus
Former MassBio CEO Joins IGC Pharma's Advisory Board to Advance AI-Powered Alzheimer's Programs - Stock Titan
India Globalization Capital : IGC Announces Results of its 2020 Annual Stockholders Meeting - marketscreener.com
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates - MSN
IGC Pharma expands CALMA trial with addition of Butler Hospital Program - Yahoo Finance
IGC Pharma Expands Phase 2 Alzheimer's Trial Site - marketscreener.com
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - Newswire.com
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - BioSpace
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addi - GuruFocus
IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health - TipRanks
IGC Pharma expands CALMA clinical trial - TipRanks
IGC Pharma Accelerates Alzheimer's Breakthrough: Key Research Center Joins Phase 2 Trial - Stock Titan
IGC Pharma posts promising interim data for Alzheimer’s therapy - MSN
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances - BioSpace
Breakthrough: New Alzheimer's Drug Cuts Sleep Disturbances by 78% in Phase 2 Trial - Stock Titan
IGC adds new clinical site in Canada for Alzheimer’s agitation therapy trial - Clinical Trials Arena
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences - BioSpace
IGC Pharma Adds Canadian Site to Phase 2 Trial of Investigational Alzheimer's Dementia Therapy - MarketScreener
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida - ACCESS Newswire
IGC Pharma's Alzheimer's Drug Shows Promise: CALMA Trial Adds New Florida Site - StockTitan
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" - ACCESS Newswire
IGC Pharma Catches Analyst Attention: $4.25 Target Set as Clinical Milestones Approach - StockTitan
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" - ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results” | FinancialContent - Financial Content
IGC Pharma's Alzheimer's Drug Trial Gets Positive Analyst Coverage - Stock Titan
IGC Pharma, Inc. (IGC) Advances AI Model to Enhance Alzheimer’s Diagnosis - Insider Monkey
IGC Pharma Inc (IGC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.19%
0.27%
자본화:
|
볼륨(24시간):